Study Review – GLOW Study update: Long-term efficacy and safety of ibrutinib-venetoclax in first-line CLL

As part of our ongoing aim to bring you reports of new developments, we have added a review which summarises key results from the GLOW study and presents updated data from the 67-month follow-up analysis.

Independent commentary for the review has been provided by Dr Joel Wight, a clinical and laboratory haematologist at the Townsville University Hospital with research interests in lymphoma and CLL.

 

Please login below to download this issue (PDF)

Subscribe